| 题名 | A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer. |
| 作者 | Zhang Y1, Gao C, Qu W, Gao Y, Zhu S, Zhang S, He W, Yu Y. |
| 杂志 | Cancer Invest. 2015 Jul;33(6):241-5. |
| 链接 | https://www.ncbi.nlm.nih.gov/pubmed/?term=A+Randomized+Phase+II+Study+of+Erlotinib+Plus+Nab-Paclitaxel+Versus+Erlotinib+Alone+as+Second-Line+Therapy+for+Chinese+Patients+with+Advanced+EGFR+Wild-Type+… |
急求
| 欢迎光临 科研速递论坛 (http://www.expaper.cn/) | Powered by Discuz! X2.5 |